Loading clinical trials...
Loading clinical trials...
Study of the Efficiency and Security of NIVOLUMAB Therapy, Used in Immuno-stimulation, in Hospitalized Obese Individuals at Risk to Evolve Towards Severe Forms of COVID-19 Infection. Multicentric, Paralleled, Randomized, Controlled Trial
Conditions
Interventions
NIVOLUMAB
Routine standard of care
Locations
1
France
Hôpital Lyon Sud Service Endocrinologie, Diabète et Nutrition
Pierre-Bénite, France
Start Date
June 15, 2020
Primary Completion Date
June 15, 2021
Completion Date
September 15, 2021
Last Updated
June 4, 2020
Lead Sponsor
Hospices Civils de Lyon
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions